Bladder cancer: Can we move beyond chemotherapy?

Current Oncology Reports

Volumn 12, Issue 4, 2010, Pages 278-283

  Siefker Radtke, Arlene ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti CTLA 4 antibody; Aurora A kinase; Bevacizumab; Bladder cancer; Chemotherapy; Cisplatin; EGFR; EMT (epithelial to mesenchymal transition); Gemcitabine; IFN; Ifosfamide; Immunology; Novel agents; NY ESO 1; Tarceva; Trastuzumab; Urothelial cancer; Vaccine; VEGF

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; INTERFERON; METHOTREXATE; NY ESO 1 ANTIGEN; PACLITAXEL; PROTEIN P53; TRASTUZUMAB; VINBLASTINE;

ADJUVANT THERAPY; ADVANCED CANCER; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT CANCER; VIRAL GENE DELIVERY SYSTEM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; GENE THERAPY; HUMANS; IMMUNOTHERAPY; URINARY BLADDER NEOPLASMS;

EID: 77956394387     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0104-5     Document Type: Review

References (42)

1. Sternberg CN, Yagoda A, Scher HI, et al.: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985, 133:403-407.
2. von der Maase H, Hansen SW, Roberts JT, et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
3. Grossman HB, Natale RB, Tangen CM, et al.: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [erratum appears in N Engl J Med 2003, 349:1880]
4. N Engl J Med 2003, 349:859-866.
5. Logothetis CJ, Dexeus FH, Finn L, et al.: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990, 8:1050-1055.
6. Logothetis CJ, Finn LD, Smith T, et al.: Escalated MVAC with or without recombinant human granulocyte-macrophage colonystimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial. J Clin Oncol 1995, 13:2272-2277.
7. Seidman AD, Scher HI, Gabrilove JL, et al.: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1993, 11:408-414.
8. Loehrer PJ Sr, Elson P, Dreicer R, et al.: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group trial. J Clin Oncol 1994, 12:483-488.
9. Bamias A, Aravantinos G, Deliveliotis C, et al.: Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004, 22:220-228.
10. Siefker-Radtke AO, Millikan RE, Tu SM, et al.: Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002, 20:1361-1367.
11. Sternberg CN, de Mulder PH, Schornagel JH, et al.: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001, 19:2638-2646.
12. Siefker-Radtke A, Millikan, RE, Kamat, AM, et al.: A phase II trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine (IAG), followed by cisplatin, gemcitabine, and ifosfamide (CGI) in locally advanced urothelial cancer: Final results from the M. D. Anderson Cancer Center. J Clin Oncol 2008, 26:269s.
13. Bajorin DF, McCaffrey JA, Dodd PM, et al.: Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules. Cancer 2000, 88:1671-1678.
14. Siefker-Radtke A, Kamat A, Williams D, et al.: A phase II randomized four-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from the M. D. Anderson Cancer Center. J Clin Oncol 2009, 27:251s. This clinical trial used a novel statistical design in sequential therapy that incorporates response to continue treatment that is working, with early re-randomization in the setting of suboptimal response.
15. Milowsky MI, Nanus DM, Maluf FC, et al.: Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol 2009, 27:4062-4067. This is a sequential clinical trial design using a fixed schedule of chemotherapy.
16. Thall PF, Millikan RE, Sung HG: Evaluating multiple treatment courses in clinical trials. Stat Med 2000, 19:1011-1028.
17. Siefker-Radtke AO, Kamat AM, Grossman HB, et al.: Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 2009, 27:2592-2597. This is the first clinical trial in small cell urothelial cancer. Though it is a small clinical trial, it suggests a potential impact for neoadjuvant chemotherapy in small cell of the bladder.
18. Siefker-Radtke AO, Gee J, Shen Y, et al.: Multimodality management of urachal carcinoma: The M. D. Anderson Cancer Center experience. J Urol 2003, 169:1295-1298.
19. Shariat SF, Lotan Y, Karakiewicz PI, et al.: P53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol 2009, 182:907-913.
20. Millikan R, Dinney C, Swanson D, et al.: Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001, 19:4005-4013.
21. Mhawech-Fauceglia P, Fischer G, Beck A, et al.: Raf1, Aurora-A/ STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol 2006, 32:439-444.
22. Slaton JW, Millikan R, Inoue K, et al.: Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004, 171:570-574.
23. Sen S, Zhou H, Zhang RD, et al.: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002, 94:1320-1329.
24. Park HS, Park WS, Bondaruk J, et al.: Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 2008, 100:1401-1411.
25. Nguyen PL, Swanson PE, Jaszcz W, et al.: Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 1994, 101:166-176.
26. Blehm KN, Spiess PE, Bondaruk JE, et al.: Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: Implications for therapy. Clin Cancer Res 2006, 12:4671-4677.
27. Black PC, Brown GA, Inamoto T, et al.: Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008, 14:1478-1486.
28. Adam L, Zhong M, Choi W, et al.: MiR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009, 15:5060-5072. This recent publication suggests a role for miR-200 as a regulatory mechanism for EMT in urothelial cancer.
29. Jimenez RE, Hussain M, Bianco FJ Jr, et al.: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001, 7:2440-2447.
30. Lonn U, Lonn S, Friberg S, et al.: Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995, 1:1189-1194.
31. Lee SE, Chow NH, Chi YC, et al.: Expression of c-erbB-2 protein in normal and neoplastic urothelium: Lack of adverse prognostic effect in human urinary bladder cancer. Anticancer Res 1994, 14:1317-1324.
32. Hussain M, Petrylak D, Dunn R, et al.: Trastuzumab (T), Paclitaxel (P), Carboplatin (C), and Gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial. J Clin Oncol 2005, 23:379s.
33. Goddard JC, Sutton CD, Furness PN, et al.: Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 2003, 9:2583-2586.
34. Bochner BH, Cote RJ, Weidner N, et al.: Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995, 87:1603-1612.
35. Crew JP, O'Brien T, Bradburn M, et al.: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997, 57:5281-5285.
36. Yang CC, Chu KC, Yeh WM: The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 2004, 22:1-6.
37. Bernardini S, Fauconnet S, Chabannes E, et al.: Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001, 166:1275-1279.
38. Benedict WF, Tao Z, Kim CS, et al.: Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFNalpha protein. Mol Ther 2004, 10:525-532.
39. Nagabhushan TL, Maneval DC, Benedict WF, et al.: Enhancement of intravesical delivery with Syn3 potentiates interferonalpha2b gene therapy for superficial bladder cancer. Cytokine Growth Factor Rev 2007, 18:389-394.
40. Sharma P, Shen Y, Wen S, et al.: CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sc U S A 2007, 104:3967-3972. This recent tissue-based study suggests the potential impact of tumor recognition by the immune system.
41. Sharma P, Gnjatic S, Jungbluth AA, et al.: Frequency of NY-ESO- 1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun 2003, 3:19.
42. Sharma P, Bajorin DF, Jungbluth AA, et al.: Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 2008, 31:849-857. This clinical trial uses vaccine to induce immune responses in urothelial cancer patients.